Sclerosis, which is known as SSC or more commonly [indiscernible] Derma.
Throughout the past year, we have also greatly enhanced our mechanistic understanding of the way in which [indiscernible] is confirming its anti-inflammatory effects.
NRP-2 is highly expressed on activated immune cells during an inflammatory response, notably myeloid cells, including monocytes and macrophages.
guides into of is a to our epsofitamat site at less NRPX, resolve inflammation of macrophage inflammation. binding the monocytes differentiation the proinflammatory By subtype that
such hallmark lead can the progression myeloid a uncontrolled to is fibrosis. inflammation where persistent Disregulated driven diseases an of ILD inflammation of
now understanding, breakthrough clarity in for even ILD. and may confidence this new have a With as represent we greater to why treatment
will where patients. for Current indication prevalent the symptomatic in approximately XX% XX% nearly psoriasis immunosuppressive high patients is standard primarily fibrosis. ILD, burden lead Our oral highly form will of resulting limited has a disease and corticosteroids, is most that clinical have care lung broadly and with disease comes a effects, for of develop treatment evidence, toxic of side
X with at more SLT expected sarcoidosis. centers We're pivotal with global placebo patients largest be study, which the context III taper in the study a thus evaluating This made interventional with is than in study far the sarcoidosis. in is in a steroid enrolling progress to X ever of pulmonary compared is to we've conducted this XX Phase countries. study currently pleased
so is focus, our Completing year. enrollment in [indiscernible] second and in we're quarter primary anticipating the this of
continue study trial. to In the requested principal have from as principles, PIs, we've inquiries patients months, completed patients are study the past they investigators few once multiple XX-week EPZO-FIT completed received study, whose treatment or the
The have has the patients well on study. what to the rather to either as and of study some PIs they prior and study, we have returning treatment blinded the patients received placebo. patients or want had X to are treatment received that than performed continue to regimen While all drug suggested efzofitimod part feedback
For reluctant are do. which that are entail may patients to increasing some resuming dose, many steroid patients,
This or complete the for the company Based of on the EPZO-FIT remain EPZO-FIT. patient in patients Expanded who as decided of Program, blinded have completing trial. individual EPZO-FIT. the to to The are individual is occurred that efzofitimod duration of beyond allow or designed this an part treatment to process PI patient patients patients to Access EAP, access we feedback, will clinical EAP who implement for
evaluation is monitoring EAP. to completed Safety data additional of key this XX component database prior from the from that were weeks efzofitimod based any the Board, clinical included able existing review DSMB, a on safety patients implement data or of We data EPZO-FIT of and from of safety and treatment. a studies tolerability program safety which
demand, review DSMB to feedback entrusted data without typically modification, this this their The recommended been many us unblinded, but based in and types the early, those study. of are study after the their who safety EAP study to dedicated have suggesting while not support with And from part important individual help has participating only continue EAPs to proceed we decided major patient no patients implement on concerns. in implemented time and by
develop to commitment effective reflects sarcoidosis in safe a community treatment need. work program as our ongoing those the we for This to and
options for indication for the of [indiscernible] is treat underlying multiple connective SSC not commonly sarcoidosis is in the and to enrollment which ILD do placebo is efzofitimod efzofitimod or study, evaluating patients second Our Current disease leading tissue currently is fine at open quarter patient first a SSC SSC dosed with a where form mortality. compared of improve quality ILD. centers last proof-of-concept is occurs in treatment U.S. of the disease study This like limited life. ILD. cause and are the
and study a year. the on study this from we data generating on later expect this provide focused in We're XXXX, to
efzofitimod represent our billion a current the be action ILDs forms market standard of We more XXX than indications to mechanism to billion that opportunity. unique of safety the of may This able profile in [indiscernible] to $X comprise of any not disrupt that potential the pathology address potential care. does other program $X where include efzofitimod, and complex estimate X desirable clinical immune global for
While our is stages human platform continue focus from we clinical intellectual pipeline program generate our for as primary efzofitimod, candidates. utilize at new domains all to property state, our engine XX to or IP an our TNA leverage covering and
pathways the novel domains pathways are may role signaling synthetases in receptors that areas CNA benefit. response therapeutic we identifying can in essential these play and proteins proteins diverse elucidate disease these extracellularly By explore cellular humans. to ancient evolved they and have for have regulate extracellular domains, where
ATYR-XXXX, Our with advanced and X most ATYR-XXXX in interactions that have fibrosis. in which both or preclinical specific candidates development targets have of tRNA implications synthetase
DARs, inducing persistence These selectively myopia FGFRX, latent or of X ATYR-XXXX, myofibroblast glass. protein targeting the transforming fibrosis beta binding targets a fibroblast factor growth is respectively. a of or LTBPX exerts is effects antifibrotic dated include tRNAsynthetase apoptosis its and key growth which factor of receptor by hallmark derived from domain X a of the pathology, which
indications by it efzofitimod radar regulator in like ways including support particular, interact domains The targets was of kidney which and some biology XXX. mechanism to immune targets continues well-known able previously extracellularly fibrosis. the like with been way lung, like This NRPX may platform hidden unlock broad in under or therapeutic the more our XXXX like applications an that and unique inspire we from and these to in liver have in appended
innovation process that example generate me-too is is traditional pathways signaling of an platform, exploiting signaling existing of drug maintain to is pathways increasingly discovery, bio This based which to have evolved billions the that a disrupt over on on reliant potential therapies. years and has excellent to homeostasis
tRNA lead grow stronger conviction Our advances. the synthetase as transformative as potential of continues to medicines to our to to research biology
now Broadfoot, to our Jill Financial review I'll it results. Chief our over to turn Officer, financial
